The phosphotungstate-MgCl , method for precipitating very low density and low density lipoproteins from plasma precipitates up to about 7 % of high density lipoprotein.
method for high density lipoprotein cholesterol measurement if the cholesterol assay is unaffected by either heparin or MnCI 2. High density lipoprotein cholesterol results, using this method, are higher than with the phosphotungstate MgCI2 method and lower than with the heparin MnCl 2 method when the MnCl2 final concentration is 0·046 mol/I, Over the last few years the plasma concentration of high density lipoprotein cholesterol (HDL-cholestero!) has been established as a major negative risk factor for ischaemic heart disease.' 2.The cheapest and most commonly used method for estimating plasma HDL-cholesterol is to precipitate very low density and low density lipoproteins (VLDL and LDL, each containing apolipoprotein B as a major protein constituent) and assume that the cholesterol remaining in the supernatant is HDL-cholesterol. Two of the most commonly used methods for precipitating VLDL and LDL are with heparin and manganous chlorides 4 and with sodium phosphotungstate and magnesium chloride.P s In a recent issue of the Association of Clinical Biochemists News Sheet? an article on HDL-cholesterol analysis noted that some HDL may be precipitated by phosphotungstate-MgCls but gave no literature reference to support this. At that time, to the best of our knowledge, there was no published work to support this statement.
In the present investigation we have confirmed that the use of phosphotungstate-MgCl 2is associated with lower supernatant cholesterol concentrations than ifheparin-MnCl2 is used. We have shown that the difference is due to precipitation of some HDL by phosphotungstate-MgCls but not by heparin-MnCh.
Methods
Published methods for LDL and VLDL precipitation with heparin-MnCl2 3 4 and phosphotungstate-MgC125 6 were used. The concentrations of cholesterol apolipoprotein B (a major protein constituent of LDL and VLDL, but not of HDL) and of 125I-labelled LDL and HDL in the supernatant were measured.
Blood was taken from the antecubital fossa vein and immediately added to dry disodium EDTA (final concentration 1 g/I). Plasma was promptly separated by low-speed centrifugation at room temperature. Plasma was stored at 4°until analysis (less than one week later).
Cholesterol and triglyceride analyses were performed by the Lipid Research Clinic AA-II method." Apolipoprotein B was measured by electroimmunoassay ('rockets') using monospecific antibody in a standard method.f Plasma LDL (d 1-030-1'050) and HDL (d 1'070-1'21) were isolated by ultra-centrifugation using standard techniques. 9 Each lipoprotein fraction was prepared at 4°by ultracentrifugation at 40 000 rev/min in a Spinco Type 40 rotor, once at the lower density limit (22h for LDL, 40h for HDL), then twice at the higher density limit (4Oh for LDL and HDL), in solutions containing 0·1 gil disodium EDTA. Solution densities were checked with a Westphal specific gravity densitometer (Griffin and George, London, UK). No contaminating albumin or other proteins were demonstrated by immunoelectrophoresis in 1 % agarose, staining with Coomassie Brilliant Blue R (Sigma, St. Louis, Mo, USA).
LDL and HDL were iodinated with 125 1 using a modification of the ICI method.w After iodination, to a specific activity of approximately 10 x 10 3 ct/ min per mg HDL protein and 1 x 10 3 ct/rnin per mg LDL protein, 'free iodide' was separated by passage down a Sephadex G-25 column, and lipoprotein solutions were exhaustively dialysed in 0'15 mol/l NaCI. The most concentrated iodinated fraction was added in tracer amounts to plasma from blood taken into dry disodium EDTA to an EDTA concentration of I mg/rnl, From the sample containing 1251-LDL, 1·0 % of radioactivity could be extracted with chloroform, and 97'5 % of radioactivity was precipitated with an equal volume of 20% (w/v) trichloroacetic acid at 4°C. From the sample containing 1251-HDL the relevant figures were 1'3% and 97'7% respectively. It was assumed that 2·5 % of 1251_LDL and 2·3 % of 1251-HDL were non-precipitable, and this proportion of total radioactivity was subtracted from measured counts when appropriate (eg, when LDL was precipitated, 2·5 % of total radioactivity was subtracted from supernatant radioactivity).
Heparin was obtained from Riker Laboratories, California, USA. Other biochemicals were highly purified or analytical reagent grade.
Results

PHOSPHOTUNGSTATE-MAGNESIUM CHLORIDE
All 1251-LDL tracer added to series of 14 normolipidaemic plasma samples from laboratory personnel was precipitated by phosphotungstate-Mgflls. Apolipoprotein B could not be demonstrated immunologically in the supernatant; 6·9 ± 2'9% (mean ± SD) of 1251-HDL tracer added to 12 normolipidaemic plasma samples was precipitated by phosphotungstate-MgCI2.
HEPARIN-MANGANESE CHLORIDE
When the final concentration of MnCI2 was 0·092 Calvert, Yeates, and Mannik mol/I, as recommended by Warnick and Albers.' apolipoprotein B was immunologically undetectable in the supernatant in 52 consecutive normolipidaemic samples «5 mg/I, ie, apolipoprotein-B-associated cholesterol <10 mg/l), Twenty plasma samples had heparin-MnCl2added to a final MnCI2 concentration of 0'046 mol/I, as originally recommended for the measurement of HDL-cholesteroI. 3 The supernatant of these contained apolipoprotein B equivalent to 23 ± 7 mg/l (mean ± SD) or 3'4 % of total plasma apolipoprotein B (678 ± 122 mg/l), In a later series of 33 plasma samples, unprecipitated apolipoprotein B was 9 ± 6 mg/I or 1·2 % of total plasma apolipoprotein B (750 ± 163 mg/I),
No 125I_HDL was precipitated with MnCI2 at either 0·046 or 0'092 rnol/l final concentration.
When 125I-LDL tracer was added to 16 normolipidaemic plasma samples and LDL precipitated (MnCh final concentration 0'046), 2·0 ± 0·3 % of 1251-LDLremained in the supernatant (mean ± SD). With a MnCI2 final concentration of 0·092 rnol/l the 125I-LDL in the supernatant was unchanged (2'0 ± 0·5 % of 125I-LDL). While the MnCh concentration clearly affected the proportion of immunologically identifiable apolipoprotein B (LDL) in the supernatant (in that all immunologically detectable apolipoprotein B was precipitated when the MnCh final concentration was 0'092 mol/l but not when it was 0'046 mol/l), we are unable to explain our failure to measure this effect using 1251-LDL tracer. The 125I_LDL tracer may have contained a minor nonprecipitable protein constituent (eg, apolipoprotein A or DIl), which was undetected.
COMPARISON BETWEEN TWO PRECIPITATION METHODS
HDL-cholesterol measurements were consistently lower with the phosphotungstate-MgCls method than with the heparin-MnCh method (Fig. 1 ), consistent with precipitation of some HDL with phosphotungstate. The linear regression through the points in Fig. 1 was 2'5 ± 0'2% (±SEM) below the equivalence line for the two methods when HDLcholesterol (by heparin-Mnf.l-) was 1·0 mmol/I and 6·9 ± 0·3 % below when HDL-cholesterol (by heparin-Mnflls) was 1'5 mmol/l, consistent with the suggestion that the phosphotungstate-MgCh method precipitates up to 7 % of HDL-cholesteroI.
HDL cholesterol measurements with the heparin-MnCl2 method were lower when the concentration of MnCI2 was 0'092 mol/I than when it was 0·046 rnol/l (Fig. 2) , consistent with incomplete precipitation of apolipoprotein B at the lower MnCI2 concentration. 
Discussion
Plasma HDL-cholesterol concentrations measured by the phosphotungstate-MgCh method are consistently lower than those measured by the heparin-MnClz method. This difference seems to be mainly, or perhaps entirely, due to precipitation of a small amount (up to about 7 %) of HDL-eholesterol by phosphotungstate-MgClz but not by heparin-MnCh. The difference is not due to differential precipitation of either cholesterol-rich HDL<.,, which carries the arginine-rich apolipoprotein E 12 or of apolipoprotein-B containing Lp(a),13 both of which are precipitated by heparin-MnClz.
Warnick and Albers! suggested that the then standard heparin-MnCh precipitation techniques be modified so that the MnCh final concentration is increased from 0'046 mol/l to 0·092 mol/I. We have found VLDL and LDL precipitation at the higher MnClz concentration to be complete and reliable, and precipitation at the lower MnClz concentration to be frequently incomplete.
The heparin-MnClz method, with heparin 1'081 ·3 g/l and MnCh 0·092 mOI/1 final concentration, is the preferred method for HDL-cholesterol quantitation if the cholesterol assay is unaffected by either heparin or MnClz.
